You are here

Clinical Trials: Cord Blood

Condition:   Hematologic Malignancy
Intervention:   Biological: Transplantation of cord blood expanded with UM171
Sponsors:   Maisonneuve-Rosemont Hospital;   Canadian Cancer Society Research Institute (CCSRI);   Canadian Institutes of Health Research (CIHR);   Hopital de l'Enfant-Jesus;   Vancouver General Hospital;   St. Justine's Hospital
Recruiting - verified March 2017
Condition:   Lymphoma
Interventions:   Procedure: Allogeneic stem cell transplantation;   Drug: Fludarabine;   Drug: Thiotepa;   Drug: Methotrexate
Sponsors:   Massachusetts General Hospital;   Adienne SA;   Dana-Farber Cancer Institute
Withdrawn - verified March 2017
Condition:   Hematologic Neoplasms
Intervention:   Procedure: Allogeneic (Allo) hematopoietic stem cell transplantation
Sponsor:   Institut Paoli-Calmettes
Recruiting - verified March 2017
Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions:   Biological: haplo-identical cells (donor);   Biological: umbilical cord blood unit (CBU)
Sponsor:   Weill Medical College of Cornell University
Condition:   Hematologic Neoplasms
Intervention:   Procedure: T-Cell replete haplo-transplant
Sponsors:   University of Calgary;   The Canadian Blood and Marrow Transplant Group
Condition:   Viral Infections After HSCT
Intervention:   Biological: VSTs
Sponsor:   Catherine Bollard
Recruiting - verified August 2017
Condition:   Severe Hypoxic-ischemic Encephalopathy
Interventions:   Drug: HPDSC;   Drug: Cord blood
Sponsors:   New York Medical College;   Celgene
Not yet recruiting - verified May 2017
Conditions:   Leukemia;   Lymphoma
Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Radiation;   Procedure: Fucosylated Regulatory T Cells;   Procedure: Cord Blood Infusions;   Drug: Mycophenolate mofetil;   Drug: Sirolimus;   Procedure: Bone Marrow Aspiration;   Drug: G-CSF;   Procedure: Non-Fucosylated Regulatory T Cells
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Targazyme, Inc.;   Cancer Prevention Research Institute of Texas
Recruiting - verified April 2017
Condition:   Stroke
Intervention:   Biological: allogeneic umbilical cord blood
Sponsor:   Joanne Kurtzberg, MD
Completed - verified March 2017
Condition:   Bronchopulmonary Dysplasia
Intervention:   Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells
Sponsors:   Medipost America Inc.;   Medipost Co Ltd.